ABSTRACT
OBJECTIVES The aim of this study was to describe the frequency, causes, factors, and costs associated with right heart failure encounters.
BACKGROUND Multiple studies have looked into heart failure readmissions but there is no study to our knowledge specifically analyzing patients with right heart failure.
METHODS Patients with right heart failure diagnosis were identified using the 2017 Nationwide Readmission Database (NRD) and were evaluated for the rates, predictors, and costs of unplanned 30 days readmission. Weighted analysis was performed to obtain nationally representative data.
RESULTS We identified 7142 patients with right heart failure of whom 21% had an unplanned readmission within 30 days of the index discharge. Patients with history of Coronary artery bypass grafting (p=0.033; OR 2.359; 95% CI 1.071 - 5.197), Chronic kidney disease (p<0.001; OR 1.607; 95% CI 1.402 - 1.843), atrial fibrillation (p=0.014; OR 1.417; 95% CI 1.072–1.873) had high odds of unplanned 30 day readmissions while obesity (p<0.001; OR 0.686; 95% CI 0.594 - 0.792) had negative odds of such readmissions.
CONCLUSIONS Thirty-day unplanned readmissions remain a significant issue affecting over 1 in 5 patients with right heart failure. Early unplanned readmissions are associated with significant mortality and financial burden in these patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
No Clinical trials were conducted
Funding Statement
No Funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is based on publicly available deidentified database and was approved for exempt status by the IRB at University of South Alabama
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimers: GCF discloses consulting for Abbott, Amgen, AstraZeneca, Bayer, Edwards, Janssen, Medtronic, Merck, and Novartis.
Sources of support: None
Data Availability
All data is publicly available, we utilized the NRD Database
Abbreviations
- NRD
- Nationwide Readmission Database
- ICD
- International Classification of Diseases
- CMS
- Centers for Medicare & Medicaid Services
- RSRR
- Risk-Standardized Readmission Rates
- HRRP
- Hospital Readmissions Reduction Program
- CAD
- coronary artery disease
- CVA
- Cerebro- Vascular accidents
- CABG
- Coronary artery bypass grafting
- GI
- Gastrointestinal
- COPD
- Chronic obstructive pulmonary disease
- CKD
- Chronic kidney disease
- AKI
- Acute kidney injury
- CCSR
- Clinical Classification Software refined
- IQR
- Inter Quartile Range
- APR-DRG
- All Patient Refined-Diagnosis Related Group
- MACCE
- Major Adverse Cardiovascular and Cerebrovascular Events
- PAD
- Peripheral artery disease
